CB2 cannabinoid receptors as an emerging target for demyelinating diseases: from neuroimmune interactions to cell replacement strategies
Open accessThe DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.
Abstract
Amongst the various demyelinating diseases that affect the central nervous system, those induced by an inflammatory response stand out because of their epidemiological relevance. The best known inflammatory‐induced demyelinating disease is multiple sclerosis, but the immune response is a common pathogenic mechanism in many other less common pathologies (e.g., acute disseminated encephalomyelitis and acute necrotizing haemorrhagic encephalomyelitis). In all such cases, modulation of the immune response seems to be a logical therapeutic approach. Cannabinoids are well known immunomodulatory molecules that act through CB 1 and CB 2 receptors. While activation of CB 1 receptors has a psychotropic effect, activation of CB 2 receptors alone does not. Therefore, to bypass the ethical problems that could result from the treatment of inflammation with psychotropic molecules, considerable effort is being made to study the potential therapeutic value of activating CB 2 receptors. In this review we examine the current knowledge and understanding of the utility of cannabinoids as therapeutic molecules for inflammatory‐mediated demyelinating pathologies. Moreover, we discuss how CB 2 receptor activation is related to the modulation of immunopathogenic states. British Journal of Pharmacology (2008) 153, 216–225; doi:10.1038/sj.bjp.0707466; published online 24 September 2007
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Functional neurogenesis in the adult hippocampus
van Praag, H., Schinder, A. F., Christie, B. R., Toni, N., Palmer, T. D., & Gage, F. H. (2002) · Nature · doi:10.1038/4151030a · Cited by 2,853 · cited 1×
“Neural progenitor cells located in the SGZ of the hippo- campus proliferate and give rise to immature neurons (Kempermann et al., 2003), which become functional neurons within 4–6 weeks (Van Praag et al., 2002).”
BackgroundThe Endocannabinoid System as an Emerging Target of Pharmacotherapy
Pacher, P., Bátkai, S., & Kunos, G. (2006) · Pharmacological Reviews · doi:10.1124/pr.58.3.2 · Cited by 2,077 · cited 2×
“gen-activated protein kinases (reviewed in Howlett and Mukhopadhyay, 2000; Pacher et al., 2006; Fernandez-Ruiz et al., 2007).”
BackgroundAxonal damage in acute multiple sclerosis lesions
Ferguson, B. (1997) · Brain · doi:10.1093/brain/120.3.393 · Cited by 1,532
Identification and Functional Characterization of Brainstem Cannabinoid CB2Receptors
Van Sickle, M. D., Duncan, M., Kingsley, P. J., Mouihate, A., Urbani, P., Mackie, K., Stella, N., Makriyannis, A., Piomelli, D., Davison, J. S., et al. (2005) · Science · doi:10.1126/science.1115740 · Cited by 1,470
Origin of oligodendrocytes in the subventricular zone of the adult brain
Menn, B., Garcia-Verdugo, J. M., Yaschine, C., Gonzalez-Perez, O., Rowitch, D., & Alvarez-Buylla, A. (2006) · The Journal of Neuroscience · doi:10.1523/jneurosci.1299-06.2006 · Cited by 972 · cited 5×
“oligodendrocyte precursors that migrate towards the adjacent areas of the white matter (Doetsch et al., 1999; Menn et al., 2006).”
BackgroundInfluentialViviani, B., Bartesaghi, S., Gardoni, F., Vezzani, A., Behrens, M. M., Bartfai, T., Binaglia, M., Corsini, E., Di Luca, M., Galli, C. L., et al. (2003) · The Journal of Neuroscience · doi:10.1523/jneurosci.23-25-08692.2003 · Cited by 893
Dendritic cells permit immune invasion of the CNS in an animal model of multiple sclerosis
Greter, M., Heppner, F. L., Lemos, M. P., Odermatt, B. M., Goebels, N., Laufer, T., Noelle, R. J., & Becher, B. (2005) · Nature Medicine · doi:10.1038/nm1197 · Cited by 862 · cited 2×
“These cells have been involved in the pathogenesis of MS and related animal models (Greter et al., 2005) even though there is no direct evidence that activation of CB2 receptors modulates their activity in MS or in animal models.”
BackgroundCannabinoid CB2 receptors: immunohistochemical localization in rat brain
Gong, J.-P., Onaivi, E. S., Ishiguro, H., Liu, Q.-R., Tagliaferro, P. A., Brusco, A., & Uhl, G. R. (2006) · Brain Research · doi:10.1016/j.brainres.2005.11.035 · Cited by 820
Selective Vulnerability of Late Oligodendrocyte Progenitors to Hypoxia–Ischemia
Back, S. A., Han, B. H., Luo, N. L., Chricton, C. A., Xanthoudakis, S., Tam, J., Arvin, K. L., & Holtzman, D. M. (2002) · The Journal of Neuroscience · doi:10.1523/jneurosci.22-02-00455.2002 · Cited by 795 · cited 1×
“Similarly, oligodendrocytes are sensitive to microglial- derived free-radicals and mediators of inflammation (Molina-Holgado et al., 2001; Back et al., 2002; Li et al., 2005).”
BackgroundEpidemiologic evidence for multiple sclerosis as an infection
Kurtzke, J. F. (1993) · Clinical Microbiology Reviews · doi:10.1128/cmr.6.4.382 · Cited by 472 · cited 2×
“triggers an immune response that, by diverse mechanisms is finally directed towards myelin self-peptides (Kurtzke, 1993; Johnson, 1994; Coraddu et al., 1998; Haines et al., 1998).”
Background
Cited by
Cannabinoids as Novel Anti-Inflammatory Drugs
Nagarkatti, P., Pandey, R., Rieder, S. A., Hegde, V. L., & Nagarkatti, M. (2009) · Future Medicinal Chemistry · doi:10.4155/fmc.09.93 · Cited by 555
“In general, cannabinoids are useful in treating MS because they have neuroprotective as well as immunosuppressive properties [44,45].”
Cabral, G. A., & Griffin-Thomas, L. (2009) · Expert Reviews in Molecular Medicine · doi:10.1017/s1462399409000957 · Cited by 408
“Chemistry 283, 13320-13329 153 Arevalo-Martin, A. et al. (2003) Therapeutic”
Hern, J. A., Baig, A. H., Mashanov, G. I., Birdsall, B., Corrie, J. E. T., Lazareno, S., Molloy, J. E., & Birdsall, N. J. M. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0907915107 · Cited by 383
Phytocannabinoids as novel therapeutic agents in {CNS} disorders.
Hill, A. J., Williams, C. M., Whalley, B. J., & Stephens, G. J. (2012) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2011.09.002 · Cited by 312
Lipid G Protein-coupled Receptor Ligand Identification Using β-Arrestin PathHunter™ Assay
Yin, H., Chu, A., Li, W., Wang, B., Shelton, F., Otero, F., Nguyen, D. G., Caldwell, J. S., & Chen, Y. A. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m806516200 · Cited by 311
Endocannabinoids drive the acquisition of an alternative phenotype in microglia
Mecha, M., Feliú, A., Carrillo-Salinas, F. J., Rueda-Zubiaurre, A., Ortega-Gutiérrez, S., de Sola, R. G., & Guaza, C. (2015) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2015.06.002 · Cited by 234
Self-citationAn overview of the cannabinoid type 2 receptor system and its therapeutic potential
Bie, B., Wu, J., Foss, J. F., & Naguib, M. (2018) · Current Opinion in Anaesthesiology · doi:10.1097/aco.0000000000000616 · Cited by 206
Heng, B. C., Aubel, D., & Fussenegger, M. (2013) · Biotechnology Advances · doi:10.1016/j.biotechadv.2013.08.017 · Cited by 204
“…studies have demonstrated that activating CB2 signaling has an overall anti-inflammatory effect (Ashton, 2007), making it an attractive drug target for treatment of autoimmune diseases such as multiple sclerosis (Arévalo-Martín et al., 2008) and inflammatory bowel disease (Wright et al., 2008).”
Background
Metadata
- Authors
- Arévalo‐Martín, Á., García‐Ovejero, D., Gómez, O., Rubio‐Araiz, A., Navarro‐Galve, B., Guaza, C., Molina‐Holgado, E., & Molina‐Holgado, F.
- Venue
- British Journal of Pharmacology
- Publisher
- Wiley
- Published
- 2008-01
- Volume
- 153
- Issue
- 2
- Pages
- 216-225
- ISSN
- 0007-1188 (ISSN-L)
- 1476-5381
- OpenAlex
- W2077322233
- Cited by
- 73
- References
- 15
- FWCI
- 4.51
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.